KBC Group NV Acquires 1,213 Shares of Xencor, Inc. (NASDAQ:XNCR)

KBC Group NV grew its holdings in Xencor, Inc. (NASDAQ:XNCR) by 63.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,123 shares of the biopharmaceutical company’s stock after acquiring an additional 1,213 shares during the period. KBC Group NV’s holdings in Xencor were worth $63,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Logos Global Management LP lifted its holdings in Xencor by 130.8% in the 2nd quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock worth $28,395,000 after purchasing an additional 850,000 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of Xencor by 52.9% in the second quarter. Point72 Asset Management L.P. now owns 1,261,789 shares of the biopharmaceutical company’s stock worth $23,886,000 after buying an additional 436,389 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Xencor by 9.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock worth $84,530,000 after buying an additional 335,881 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Xencor by 3.6% during the first quarter. Vanguard Group Inc. now owns 7,011,042 shares of the biopharmaceutical company’s stock worth $155,154,000 after acquiring an additional 243,793 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Xencor during the first quarter valued at $4,608,000.

Analyst Upgrades and Downgrades

Several brokerages have commented on XNCR. Royal Bank of Canada boosted their price target on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a research note on Thursday, September 26th. BMO Capital Markets reiterated an “outperform” rating and issued a $34.00 target price (up from $32.00) on shares of Xencor in a research report on Friday, November 8th. JPMorgan Chase & Co. raised their price target on Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Finally, Wedbush reiterated an “outperform” rating and set a $38.00 target price on shares of Xencor in a research report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $35.75.

Insider Activity at Xencor

In related news, VP John R. Desjarlais sold 68,684 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the completion of the sale, the vice president now directly owns 200,104 shares of the company’s stock, valued at approximately $4,698,441.92. This trade represents a 25.55 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bassil I. Dahiyat sold 3,366 shares of the company’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $24.02, for a total value of $80,851.32. Following the completion of the transaction, the chief executive officer now directly owns 352,615 shares in the company, valued at $8,469,812.30. This trade represents a 0.95 % decrease in their position. The disclosure for this sale can be found here. 5.23% of the stock is currently owned by insiders.

Xencor Stock Performance

NASDAQ XNCR opened at $25.01 on Friday. The business’s 50 day moving average price is $21.47 and its 200-day moving average price is $20.42. Xencor, Inc. has a fifty-two week low of $15.31 and a fifty-two week high of $26.84. The company has a market cap of $1.75 billion, a P/E ratio of -7.82 and a beta of 0.66. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.27. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $10.70 million for the quarter, compared to analysts’ expectations of $14.59 million. During the same quarter in the previous year, the business posted ($0.40) earnings per share. The business’s revenue was down 81.9% compared to the same quarter last year. Sell-side analysts predict that Xencor, Inc. will post -3.71 earnings per share for the current year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.